Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer
- Conditions
- Epithelial Ovarian Cancer
- Registration Number
- NCT01680575
- Lead Sponsor
- Asan Medical Center
- Brief Summary
To develop a robust prediction model to predict the occurrence of grade 3-4 neutropenia induced by adjuvant paclitaxel/carboplatin chemotherapy in patients with epithelial ovarian cancer and to validate this model.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 750
Inclusion Criteria
- Patients with FIGO stage I-IV epithelial ovarian cancer after staging or debulking surgery
- Patients who is planned to receive (prospective cohort) ro who received (retrospective cohort) adjuvant chemotherapy with paclitaxel and carboplatin
- Patients who have signed approved informed consent
Exclusion Criteria
- Uncontrolled medical disease
- Active infectious disease
- Previous pelvic radiation therapy
- Previous chemotherapy (prospective cohort)
- Patients with disease which can cause neutropenia
- Patients who will receive other targeted therapy or immunotherapy during adjuvant therapy (prospective cohort).
- Pregnant or lactating woman
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Risk prediction model for grade 3-4 chemotherapy induced neutropenia 1 year
- Secondary Outcome Measures
Name Time Method The association between mannose-binding lectin 2 gene SNP and neutropenia 1 year
Trial Locations
- Locations (1)
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center
🇰🇷Seoul, Korea, Republic of